Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GvHD prophylaxis with ATG-fresenius S in allogeneic stem cell transplantation from matched unrelated donors: A randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-Fresenius S.

Next Previous
Search
Trial Profile

GvHD prophylaxis with ATG-fresenius S in allogeneic stem cell transplantation from matched unrelated donors: A randomized phase III multicenter trial comparing a standard GvHD prophylaxis with cyclosporine A and methotrexate with additional pretransplant ATG-Fresenius S.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin; Methotrexate
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ATG-F; SCT
  • Sponsors Neovii Biotech

    • Most Recent Events

    • 26 Jun 2017 Results of 8 year follow-up published in a Neovii Biotech media release.
    • 26 Jun 2017 Results of 8-year follow-up published in the June 2017 edition of The Lancet Haematology, according to a Neovii Biotech media release.
    • 18 Jan 2016 According to a Neovii Pharmaceuticals media release, results were published in New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top